PYC Physiomics Plc

TIDMPYC

Physiomics PLC

03 October 2023

3 October 2023

Physiomics plc

("Physiomics" or "the Company")

Senior Management Announcement

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.

Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many of the top-tier pharmaceutical and CRO companies. Since obtaining his PhD in Applied Statistics, he has held a variety of senior biostatistics and programming roles across academia and industry, both working in-house and as an independent consultant. During these roles, he gained significant experience across Pre-clinical, PK/PD, Biosimilars, Phase-I, IIa, IIb, III and IV, Medical Affairs, Post-Marketing, Diagnostics, Medical Devices, Heath Technology Assessments, Health Economics and Health Related Quality of Life analysis.

The Head of Biostatistics role will help to formulate and deliver on the Company's new Biostatistics service offering. The initial focus will be to build upon the Company's existing Biostatistics strategy, working with Business Development and Senior Management to define key service offerings and identify new clients. Dr Putcha will be responsible for the delivery of new Biostatistics consulting contracts within the business and, as we grow this service line, will take a lead refining and executing on the Company's Biostatistics strategy.

Dr Jim Millen, Executive Chair and CEO commented :

"Following our announcement earlier this year that Physiomics would be expanding into adjacent areas of lifesciences R&D consulting, starting with biostatistics, we are delighted to welcome Venkata to our team. His extensive experience in the field of biostatistics will act as a strong base from which to grow this new segment of our business. We'll be providing a further update on our expansion into this field later this calendar year."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADLLFBXBLEFBX

(END) Dow Jones Newswires

October 03, 2023 02:00 ET (06:00 GMT)

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024